Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.
The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption characteristics and guiding formulation strategies. Solubility is assessed through techniques like pH-solubility profiling, which examines how the solubility of a drug changes with pH, and shake-flask or titration methods, which determine solubility in different solvents or at different pH levels. On the other hand, permeability is evaluated through methods such as mass-balance pharmacokinetic studies, in vivo intestinal perfusion studies, and permeation experiments using intestinal tissue or epithelial cell monolayers. These methods help in predicting a drug's absorption and bioavailability.
However, drugs that exhibit low solubility and permeability often face challenges with poor bioavailability. To address this, various strategies have been developed. The pharmaceutical approach alters the drug's formulation, manufacturing process, or physicochemical properties without changing the molecular structure. This can involve the use of solubilizers, particle size reduction, or the formation of amorphous solids.
The pharmacokinetic approach aims to modify the drug's chemical structure to enhance its solubility or permeability. This might include developing new chemical entities that are more soluble or permeable, or creating prodrugs that are converted into the active drug once administered.
Lastly, the biological approach explores alternative routes of administration to bypass the limitations associated with oral bioavailability. This could involve switching from an oral to a parenteral route, where the drug is administered directly into the systemic circulation, thereby avoiding the gastrointestinal tract.
Each of these approaches provides a pathway to improving drug bioavailability, ensuring that therapeutic effects are achieved more efficiently and effectively.
Bioavailability refers to the amount of unchanged drug reaching the systemic circulation.
Drugs are categorized under the biopharmaceutics classification system into four classes based on their solubility and permeability.
Drug solubility can be determined by pH-solubility profiling and shake-flask or titration methods.
Meanwhile, permeability determination methods include mass-balance pharmacokinetic studies, in vivo intestinal perfusion studies, and permeation experiments with intestinal tissue or epithelial cell monolayers.
Some drugs with low solubility and permeability have poor bioavailability, which can be overcome by pharmaceutical, pharmacokinetic, and biological approaches.
The pharmaceutical approach involves modifying the formulation, manufacturing process, or physicochemical properties without changing the drug's chemical structure.
The pharmacokinetic approach modifies the drug's chemical structure by prodrug designs or developing new chemical entities.
The biological approach involves changing the route of drug administration, such as switching from oral to parenteral routes.
繁體中文
